Research Analysts Set Expectations for PRAX Q1 Earnings

Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Praxis Precision Medicines in a research report issued on Monday, July 14th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of ($4.32) for the quarter. HC Wainwright currently has a "Buy" rating and a $105.00 target price on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($10.22) per share. HC Wainwright also issued estimates for Praxis Precision Medicines' Q2 2026 earnings at ($5.01) EPS, Q3 2026 earnings at ($5.02) EPS and Q4 2026 earnings at ($5.03) EPS.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its quarterly earnings results on Friday, May 2nd. The company reported ($3.29) EPS for the quarter, missing analysts' consensus estimates of ($3.20) by ($0.09). Praxis Precision Medicines had a negative net margin of 2,137.48% and a negative return on equity of 50.42%.

A number of other equities analysts have also weighed in on the company. Chardan Capital assumed coverage on Praxis Precision Medicines in a research note on Wednesday, May 7th. They issued a "buy" rating and a $80.00 price objective for the company. Wedbush boosted their target price on Praxis Precision Medicines from $26.00 to $28.00 and gave the company an "underperform" rating in a research report on Monday, May 5th. Oppenheimer boosted their price objective on shares of Praxis Precision Medicines from $97.00 to $115.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $80.00 price target on shares of Praxis Precision Medicines in a research report on Thursday, June 12th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $94.11.

Praxis Precision Medicines Stock Performance

Shares of Praxis Precision Medicines stock traded down $1.09 during midday trading on Wednesday, hitting $53.85. The company had a trading volume of 394,544 shares, compared to its average volume of 370,149. The company has a 50 day moving average of $43.38 and a 200 day moving average of $50.28. Praxis Precision Medicines has a 52-week low of $26.70 and a 52-week high of $91.83. The stock has a market capitalization of $1.10 billion, a P/E ratio of -5.02 and a beta of 2.60.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new stake in shares of Praxis Precision Medicines during the 4th quarter worth about $30,000. GAMMA Investing LLC raised its position in shares of Praxis Precision Medicines by 6,075.4% during the 1st quarter. GAMMA Investing LLC now owns 4,014 shares of the company's stock worth $152,000 after buying an additional 3,949 shares in the last quarter. Graham Capital Management L.P. bought a new stake in shares of Praxis Precision Medicines during the 4th quarter worth about $209,000. KLP Kapitalforvaltning AS bought a new stake in shares of Praxis Precision Medicines during the 4th quarter worth about $215,000. Finally, Envestnet Asset Management Inc. bought a new stake in shares of Praxis Precision Medicines during the 4th quarter worth about $231,000. 67.84% of the stock is owned by institutional investors and hedge funds.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.